Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
How immune cells shape our earliest breaths
Study profiles the development of immune cells in human lungs during embryonic and fetal stages, revealing their influence on epithelial cell fate and lung development.